Global Cardiovascular and Cerebrovascular Diseases Market (2023 Edition): Analysis By Drug Type, By Indication, By Region, By Country: Drivers, Trends and Forecast to 2029

Azoth Analytics has released a research report titled "Cardiovascular and Cerebrovascular Market (2023 Edition)" which provides a complete analysis of the global Cardiovascular and Cerebrovascular industry by Drug Type (Antiplatelet Agents, Anticoagulants, Antihypertensive Agents, Statins, Other Drugs) and By Indication (Hypertension, Atrial Fibrillation, Stroke, Cerebral Aneurysms, Myocardial Infraction, Other Indications) for the historical period of 2019-2022, estimated figures of 2023 and the forecast period of 2024-2029.

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, India, Japan). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

During the forecast period, 2024-2029, the Global Cardiovascular and Cerebrovascular market is expected to grow at a CAGR of 8.12%.

The Global Cardiovascular and Cerebrovascular Market is expected to generate ~USD 130 Billion by the end of 2029, up from USD 69.85 Billion in 2022. The CVD market is significant in size and continues to grow, however, at a slower pace owing to patent expirations of major drugs in the market and the rise of generics.

Cardiovascular and cerebrovascular diseases are the world's primary causes of death. As reported by the World Health Organization (WHO), there were an estimated 17,9 million cardiovascular disease-related fatalities in 2019, accounting for 32 per cent of all global deaths. Stroke and ischemic heart disease were the two most significant contributors to this burden. The prevalence of these diseases differs by region and is influenced by demographic factors, lifestyle changes, and healthcare accessibility.

Age increases the likelihood of developing cardiovascular and cerebrovascular diseases. As people age, their blood vessels become less flexible and more prone to injury, which is a major driver of the CVD industry.

Scope of the Report:

The report analyses the Cardiovascular and Cerebrovascular Market by Value (USD Billion).
The report presents the analysis of the Cardiovascular and Cerebrovascular Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
The report analyses the Cardiovascular and Cerebrovascular Market by Drug Type (Antiplatelet Agents, Anticoagulants, Antihypertensive Agents, Statins, Other drugs).
The report analyses the Cardiovascular and Cerebrovascular Market by Indication (Hypertension, Atrial Fibrillation, Stroke, Cerebral Aneurysms, Myocardial Infraction, Other Indications).
The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, Novo Nordisk, Sanofi, AstraZeneca PLC, Merck & Co., Inc., Johnson & Johnson, Pfizer, Abbott Laboratories, Bristol-Myers Squibb Co., and Bayer.

1. Market Background

1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology

2. Strategic Recommendations

2.1 Utilisation of Artificial intelligence in Diagnostics and therapeutics development
2.2 Increasing investments in R&D operations for the development of novel treatments

3. Global Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

3.1 Impact Analysis of Macro Economic Factors on the Cardiovascular and Cerebrovascular Diseases Market
3.2 Prevalence of Cardiovascular Diseases (2019)
3.3 Cardiovascular Diseases Top marketed drugs and Top Pipeline drugs
3.4 Competitive landscape for CVD drugs in Pipeline
3.5 Global Cardiovascular and Cerebrovascular Diseases Market: Dashboard
3.6 Global Cardiovascular and Cerebrovascular Diseases Market: Market Value Assessment, 2019-2029 (USD Billion)
3.7 Impact of COVID-19 on Global Cardiovascular and Cerebrovascular Diseases Market
3.8 Global Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type
- 3.8.1 Global Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Type Overview
- 3.8.2 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.8.3 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.8.4 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.8.5 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.8.6 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)
3.9 Global Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication
- 3.9.1 Global Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview
- 3.9.2 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.9.3 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.9.4 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.9.5 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.9.6 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
- 3.9.7 Global Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

4. Global Cardiovascular and Cerebrovascular Diseases Market, Regional Analysis

5. Americas Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

5.1 Americas Cardiovascular and Cerebrovascular Diseases Market: Snapshot
5.2 Americas Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
5.3 Americas Cardiovascular and Cerebrovascular Diseases Market: Key Factors
5.4 Americas Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type
- 5.4.1 Americas Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview
- 5.4.2 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.4.3 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.4.4 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.4.5 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.4.6 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)
5.5 Americas Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication
- 5.5.1 Americas Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview
- 5.5.2 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.3 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.4 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.5 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.6 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
- 5.5.7 Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
5.6 Americas Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Country
- 5.6.1 United States Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 5.6.1.1 United States Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 5.6.1.2 United States Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 5.6.2 Canada Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 5.6.2.1 Canada Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 5.6.2.2 Canada Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 5.6.3 Rest of Americas Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 5.6.3.1 Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 5.6.3.2 Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Indication

6. Europe Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

6.1 Europe Cardiovascular and Cerebrovascular Diseases Market: Snapshot
6.2 Europe Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
6.3 Europe Cardiovascular and Cerebrovascular Diseases Market: Key Factors
6.4 Europe Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type
- 6.4.1 Europe Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview
- 6.4.2 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.4.3 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.4.4 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.4.5 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.4.6 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)
6.5 Europe Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication
- 6.5.1 Europe Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview
- 6.5.2 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.3 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.4 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.5 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.6 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
- 6.5.7 Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
6.6 Europe Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Country
- 6.6.1 France Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 6.6.1.1 France Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 6.6.1.2 France Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 6.6.2 United Kingdom Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 6.6.2.1 United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 6.6.2.2 United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 6.6.3 Italy Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 6.6.3.1 Italy Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 6.6.3.2 Italy Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 6.6.4 Spain Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 6.6.4.1 Spain Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 6.6.4.2 Spain Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 6.6.5 Germany Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 6.6.5.1 Germany Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 6.6.5.2 Germany Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 6.6.6 Rest of Europe Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 6.6.6.1 Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 6.6.6.2 Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Indication

7. Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

7.1 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Snapshot
7.2 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
7.3 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Key Factors
7.4 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type
- 7.4.1 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview
- 7.4.2 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.4.3 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.4.4 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.4.5 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.4.6 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)
7.5 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication
- 7.5.1 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview
- 7.5.2 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.3 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.4 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.5 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.6 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
- 7.5.7 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
7.6 Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Country
- 7.6.1 China Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 7.6.1.1 China Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 7.6.1.2 China Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 7.6.2 Japan Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 7.6.2.1 Japan Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 7.6.2.2 Japan Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 7.6.3 India Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 7.6.3.1 India Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 7.6.3.2 India Cardiovascular and Cerebrovascular Diseases Market, By Indication
- 7.6.4. Rest of Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
  - 7.6.4.1 Rest of Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Drug Type
  - 7.6.4.2 Rest of Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market, By Indication

8. Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

8.1 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Snapshot
8.2 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Market Size and CAGR, 2019-2029 (USD Billion & CAGR)
8.3 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Key Factors
8.4 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Drug Type
- 8.4.1 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market, By Drug Type Overview
- 8.4.2 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.4.3 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.4.4 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.4.5 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.4.6 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Other Drugs, By Value, 2019H-2029F (USD Billion & CAGR)
8.5 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Segmentation: By Indication
- 8.5.1 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market, By Indication Overview
- 8.5.2 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.3 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.4 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.5 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.6 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
- 8.5.7 Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global Cardiovascular and Cerebrovascular Diseases Market
9.2 Drivers
9.3 Restraints
9.4 Trends

10. Industry Ecosystem Analysis

10.1 Macro-Economic Factor Assessment
10.2 Porter's Five Forces Model

11. Competitive Positioning

11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Cardiovascular and Cerebrovascular Diseases Market
11.4 Company Profiles
- 11.4.1 Boehringer Ingelheim
- 11.4.2 Novo Nordisk
- 11.4.3 Sanofi
11.4 .4 AstraZeneca PLC
- 11.4.5 Merck & Co., Inc.
- 11.4.6 Johnson & Johnson
- 11.4.7 Pfizer
- 11.4.8 Abbott Laboratories
- 11.4.9 Bristol-Myers Squibb Co.
- 11.4.10 Bayer

List of Figures

Figure 1: Regional Prevalence of Cardiovascular Diseases in 2019
Figure 2: Top marketed and Pipeline drugs by NPV, USDMn
Figure 3: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Value, 2019-2022 (USD Billion)
Figure 4: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Value, 2023-2029 (USD Billion)
Figure 5: Global Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, 2022 (%)
Figure 6: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 7: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Antiplatelet Agents, 2019-2029 (USD Billion)
Figure 8: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 9: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Anticoagulants, 2019-2029 (USD Billion)
Figure 10: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 11: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Antihypertensive Agents, 2019-2029 (USD Billion)
Figure 12: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 13: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Statins, 2019-2029 (USD Billion)
Figure 14: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Other drugs, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 15: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Other Drugs, 2019-2029 (USD Billion)
Figure 16: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 17: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Hypertension, 2019-2029 (USD Billion)
Figure 18: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 19: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Atrial Fibrillation, 2019-2029 (USD Billion)
Figure 20: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 21: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Stroke, 2019-2029 (USD Billion)
Figure 22: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 23: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Cerebral Aneurysms, 2019-2029 (USD Billion)
Figure 24: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 25: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Myocardial Infraction, 2019-2029 (USD Billion)
Figure 26: Global Cardiovascular and Cerebrovascular Diseases Market Size, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 27: Global Cardiovascular and Cerebrovascular Diseases Market Absolute Opportunity, By Other Indications, 2019-2029 (USD Billion)
Figure 28: Americas Cardiovascular and Cerebrovascular Diseases Market Size, By Value, 2019H-2029F (USD Billion)
Figure 29: Americas Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, 2022 (%)
Figure 30: Americas Cardiovascular and Cerebrovascular Diseases Market, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 31: Americas Cardiovascular and Cerebrovascular Diseases Market, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 32: Americas Cardiovascular and Cerebrovascular Diseases Market, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 33: Americas Cardiovascular and Cerebrovascular Diseases Market, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 34: Americas Cardiovascular and Cerebrovascular Diseases Market, By Other drugs, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 35: Americas Cardiovascular and Cerebrovascular Diseases Market, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 36: Americas Cardiovascular and Cerebrovascular Diseases Market, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 37: Americas Cardiovascular and Cerebrovascular Diseases Market, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 38: Americas Cardiovascular and Cerebrovascular Diseases Market, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 39: Americas Cardiovascular and Cerebrovascular Diseases Market, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 40: Americas Cardiovascular and Cerebrovascular Diseases Market, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 41: United States Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 42: United States Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 43: United States Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 44: United States Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 45: Canada Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 46: Canada Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 47: Canada Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 48: Canada Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 49: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 50: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 51: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 52: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 53: Europe Cardiovascular and Cerebrovascular Diseases Market Size, By Value, 2019H-2029F (USD Billion)
Figure 54: Europe Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, 2022 (%)
Figure 55: Europe Cardiovascular and Cerebrovascular Diseases Market, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 56: Europe Cardiovascular and Cerebrovascular Diseases Market, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 57: Europe Cardiovascular and Cerebrovascular Diseases Market, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 58: Europe Cardiovascular and Cerebrovascular Diseases Market, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 59: Europe Cardiovascular and Cerebrovascular Diseases Market, By Other drugs, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 60: Europe Cardiovascular and Cerebrovascular Diseases Market, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 61: Europe Cardiovascular and Cerebrovascular Diseases Market, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 62: Europe Cardiovascular and Cerebrovascular Diseases Market, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 63: Europe Cardiovascular and Cerebrovascular Diseases Market, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 64: Europe Cardiovascular and Cerebrovascular Diseases Market, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 65: Europe Cardiovascular and Cerebrovascular Diseases Market, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 66: France Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 67: France Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 68: France Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 69: France Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 70: United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 71: United Kingdom Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 72: United Kingdom Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 73: United Kingdom Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 74: Italy Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 75: Italy Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 76: Italy Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 77: Italy Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 78: Spain Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 79: Spain Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 80: Spain Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 81: Spain Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 82: Germany Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 83: Germany Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 84: Germany Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 85: Germany Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 86: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 87: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 88: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 89: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, By Value, 2022 (%)
Figure 90: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market Size, By Value, 2019H-2029F (USD Billion)
Figure 91: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, 2022 (%)
Figure 92: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 93: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 94: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 95: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 96: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Other drugs, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 97: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 98: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 99: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 100: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 101: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 102: Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 103: China Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 104: China Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 105: China Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 106: China Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 107: Japan Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 108: Japan Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 109: Japan Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 110: Japan Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 111: India Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 112: India Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 113: India Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 114: India Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 115: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Value, 2019-2029 (USD Billion & CAGR)
Figure 116: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market Value, By Drug Type, 2022 (USD Billion)
Figure 117: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, By Value, 2022 (%)
Figure 118: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market Share, By Indication, 2022 (%)
Figure 119: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market Size, By Value, 2019H-2029F (USD Billion)
Figure 120: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market Share, By Drug Type, 2022 (%)
Figure 121: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Antiplatelet Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 122: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Anticoagulants, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 123: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Antihypertensive Agents, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 124: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Statins, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 125: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Other drugs, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 126: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Hypertension, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 127: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Atrial Fibrillation, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 128: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Stroke, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 129: Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Cerebral Aneurysms, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 130 Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Myocardial Infraction, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 131 Middle East and Africa Cardiovascular and Cerebrovascular Diseases Market, By Other Indications, By Value, 2019H-2029F (USD Billion & CAGR)
Figure 132: Global Impact of Drivers and Restraints
Figure 133: Market Share of Prominent Companies of Cardiovascular and Cerebrovascular Diseases Market, 2022 (%)
Figure 134: Novo Nordisk Revenues, 2020-2022 (USD Million)
Figure 135: Novo Nordisk Revenues, By Geographic Segments, 2022 (%)
Figure 136: Novo Nordisk Revenue , By Therapeutic Area, 2022 (%)
Figure 137: Sanofi Revenues, 2020-2022 (USD Million)
Figure 138: Sanofi Revenues, By Geographic Segments, 2022 (%)
Figure 139: Sanofi Revenue , By Business Segments, 2022 (%)
Figure 140: AstraZeneca PLC Revenues, 2020-2022 (USD Million)
Figure 141: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
Figure 142: AstraZeneca PLC Revenue , By Business Segments, 2022 (%)
Figure 143: Merck & Co., Inc. Revenues, 2020-2022 (USD Million)
Figure 144: Merck & Co., Inc. Revenues, By Geographic Segments, 2022 (%)
Figure 145: Merck & Co., Inc. Revenue , By Business Segments, 2022 (%)
Figure 146: Johnson & Johnson Revenues, 2020-2022 (USD Million)
Figure 147: Johnson & Johnson Revenues, By Geographic Segments, 2022 (%)
Figure 148: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
Figure 149: Pfizer Revenues, 2020-2022 (USD Million)
Figure 150: Pfizer Revenues, By Business Segments, 2022 (%)
Figure 151: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
Figure 152: Abbott Laboratories Revenues, 2020-2022 (USD Million)
Figure 153: Abbott Laboratories Revenues, By Geographic Segments, 2022 (%)
Figure 154: Abbott Laboratories Revenue , By Business Segments, 2022 (%)
Figure 155: Bristol-Myers Squibb Revenues, 2020-2022 (USD Million)
Figure 156: Bristol-Myers Squibb Revenues, By Geographic Segments, 2022 (%)
Figure 157: Bayer AG Revenues, 2020-2022 (USD Million)
Figure 158: Bayer AG Revenues, By Geographic Segments, 2022 (%)
Figure 159: Bayer AG Revenues, By Business Segments, 2022 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Competitive landscape for CVD drugs in Pipeline

Table A3: United States Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A4: United States Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A5: United States Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A6: United States Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A7: Canada Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A8: Canada Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A9: Canada Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A10: Canada Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A11: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A12: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A13: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A14: Rest of Americas Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A15: France Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A16: France Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A17: France Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A18: France Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A19: United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A20: United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A21: United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A22: United Kingdom Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A23: Italy Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A24: Italy Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A25: Italy Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A26: Italy Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A27: Spain Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A28: Spain Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A29: Spain Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A30: Spain Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A31: Germany Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A32: Germany Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A33: Germany Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A34: Germany Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A35: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A36: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A37: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A38: Rest of Europe Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A39: China Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A40: China Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A41: China Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A42: China Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A43: Japan Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A44: Japan Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A45: Japan Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A46: Japan Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A47: India Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A48: India Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A49: India Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A50: India Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A51: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2019-2022 (USD Billion)

Table A52: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Drug Type, By Value, 2023-2029 (USD Billion)

Table A53: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2019-2022 (USD Billion)

Table A54: Rest of Asia Pacific Cardiovascular and Cerebrovascular Diseases Market, By Indication, By Value, 2023-2029 (USD Billion)

Table A55: Novo Nordisk Key Financials, 2020-2022

Table A56: Sanofi Key Financials, 2020-2022

Table A57: AstraZeneca PLC Key Financials, 2020-2022

Table A58: Merck & Co., Inc. Key Financials, 2020-2022

Table A59: Johnson & Johnson Key Financials, 2020-2022

Table A60: Pfizer Key Financials, 2020-2022

Table A61: Abbott Laboratories Key Financials, 2020-2022

Table A62: Bristol-Myers Squibb Key Financials, 2020-2022

Table A63: Bayer AG Key Financials, 2020-2022

Global Cardiovascular and Cerebrovascular Diseases Market (2023 Edition): Analysis By Drug Type, By Indication, By Region, By Country: Drivers, Trends and Forecast to 2029

Description

Table of Contents

List of Tables

Executive Summary

Table of Contents

1. Market Background

2. Strategic Recommendations

3. Global Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

4. Global Cardiovascular and Cerebrovascular Diseases Market, Regional Analysis

5. Americas Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

6. Europe Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

7. Asia-Pacific Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

8. Middle-East & Africa Cardiovascular and Cerebrovascular Diseases Market: Historic and Forecast (2019-2029)

9. Market Dynamics

10. Industry Ecosystem Analysis

11. Competitive Positioning

List of Figures

List of Figures